Pediatric Uveitis

Ilknur Tugal-Tutkun, MD

Department of Ophthalmology, Faculty of Medicine, Istanbul University, Istanbul, Turkey

Uveitis is less common in children than in adults, and its diagnosis and management can be particularly challenging. Young children are often asymptomatic either because of inability to express complaints or because of the truly asymptomatic nature of their disease. Even in advanced cases, parents may not be aware of severe visual impairment until the development of externally visible changes such as band keratopathy, strabismus, or leukocoria. Therefore, the diagnosis is often delayed and severe complications may be seen at the time of initial visit. Young children may not be cooperative for a complete ocular examination and subtle findings of intraocular inflammation such as trace cells may be easily missed in the early stages of the disease. Children, in general, tend to have more severe and chronic intraocular inflammation that frequently results in ocular complications and visual loss. In children who present with amblyopia or strabismus, a careful examination is required to rule out uveitis as an underlying cause. Delayed and variable presentations cause a distinct challenge in the diagnosis of uveitis in children, furthermore differential diagnosis also requires awareness of etiologies which are different from adults. There are unique forms of uveitis and masquerade syndromes in this age group, while some entities commonly encountered in adults are rare in children.

Keywords: Pediatric Uveitis; Juvenile Idiopathic Arthritis; Pars Planitis; Behçet Uveitis; Tubulointerstitial Nephritis and Uveitis Syndrome

EPIDEMIOLOGY

In a population-based study in Finland, the yearly incidence of uveitis was found to be 4.3 per 100,000 in children and 27.2 per 100,000 in adults; prevalence rates were 27.9 and 93.1 per 100,000 respectively.1 In a study conducted in district hospitals in the UK, the incidence of pediatric uveitis increased with age from 3.15 per 100,000 children aged 0 to 5 years, to 6.06 per 100,000 of those between 11 and 15 years of age.2 Pediatric cases account for less than 10% of all cases of uveitis in large series reported from referral centers.

As in adults, there are variations in the geographic and ethnic distribution of various infectious and noninfectious uveitic entities in children. Table 1 shows the types of involvement and the most common diagnoses in pediatric uveitis series reported from various countries.1-18 Anterior uveitis is the most common form of involvement in almost all series. Up to 60% of patients have idiopathic uveitis. Juvenile idiopathic arthritis (JIA) associated anterior uveitis is the leading cause in series reported from Northern European countries and from the USA, whereas it is less frequent in Mediterranean and Middle Eastern countries as well as in India.
In contrast, while Behçet’s disease accounts for 11% of pediatric uveitis in Turkey and 5-6% in Israel and Tunisia, it is very rare in European countries, the USA and India. Vogt-Koyanagi-Harada disease is distinctly more common in Saudi Arabia. Pars planitis has been reported as a distinct entity in some series, but was included among unspecified idiopathic cases in others. Therefore, it is difficult to compare the frequency of idiopathic pars planitis among published series. Among infectious causes of uveitis in children, toxoplasmosis is the most common etiology. Herpetic anterior uveitis is uncommon in childhood irrespective of geographic region. Tuberculosis has been reported in 3.9% of pediatric uveitis cases in India, where the disease is endemic.14

### DIAGNOSTIC ENTITIES

**JIA-associated Anterior Uveitis**

JIA is the most common systemic association of pediatric uveitis. It is defined as arthritis of at least 6 weeks’ duration without any other identifiable cause in children younger than 16 years of age. The International League of Associations for Rheumatology (ILAR) has
classified JIA into seven subtypes. Patients with systemic-onset JIA have extraocular manifestations such as fever, rash, hepatosplenomegaly, lymphadenopathy, and serositis. Uveitis is extremely rare in this subtype. The oligoarticular subtype is diagnosed when fewer than 5 joints are involved during the first 6 months of the disease. Chronic anterior uveitis is most commonly associated with oligoarticular JIA. This subtype is defined as extended oligoarthritis when more joints become involved after 6 months. Polyarticular JIA is diagnosed when 5 or more joints are affected during the first 6 months of the disease. Polyarticular JIA may be rheumatoid factor (RF) positive or negative. Uveitis is rare in the RF-positive group, however approximately 10% of patients with RF-negative polyarticular JIA develop uveitis. Psoriatic arthritis is a less common subtype of JIA which may be associated with chronic anterior uveitis in 10-20% of cases. Enthesitis-related arthritis typically occurs in older boys who are often HLA-B27 positive. Acute unilateral anterior uveitis is the typical form of ocular involvement in these patients. Patients with arthritis who do not fulfill any of these categories are classified as the "other" JIA subgroup. 19, 20

Risk factors for ocular involvement in patients with JIA include female sex, oligoarticular arthritis, young age at onset of arthritis, antinuclear antibody (ANA) seropositivity and RF seronegativity. 21

Children with chronic anterior uveitis associated with JIA are typically asymptomatic and therefore routine ophthalmologic screening is essential for early diagnosis and timely treatment. Otherwise, affected subjects may present after development of serious ocular complications and severe visual impairment. Ocular condition at the first visit is the most significant predictor of visual outcome. Onset of uveitis before or early after the onset of arthritis has also been reported as a predictor of poor visual outcome. Screening guidelines have been developed22; patients with oligo- or polyarticular JIA with onset of arthritis at 6 years of age or younger, duration of arthritis 4 years or less, and ANA-seropositivity should be screened at 3-month intervals.

JIA-associated anterior uveitis is typically bilateral, nongranulomatous, and has a chronic relapsing course. However, a granulomatous disease does not exclude the diagnosis (Fig. 1). Mutton-fat keratic precipitates (KPs) or iris nodules, reminiscent of sarcoidosis, have been reported in 24% of white and 56% of non-white patients.23 The most common complications of JIA-associated anterior uveitis include band keratopathy (Fig. 2), cataract, posterior synechiae (Fig. 3), glaucoma, maculopathy, hypotony and amblyopia.24,25 In a recent study, 84% of eyes with JIA uveitis were found to have maculopathy on optical coherence tomography.26 The presence of complications at the time of initial visit and high anterior chamber flare values by laser flare photometry are risk factors for development.
of new complications and poor visual prognosis. Early development of cataract requiring surgery has been associated with the presence of posterior synechiae at the time of diagnosis. Early immunomodulatory treatment reduces the risk of ocular complications and visual loss. Since high anterior chamber flare is associated with an increased risk of visual loss independent of anterior chamber cells, children with high flare should be treated aggressively with the aim of reducing flare to the minimum possible level.

Chronic anterior uveitis can also occur in children without systemic disease associations. In a cohort of 115 patients with chronic anterior uveitis, no significant association was found between the presence of systemic disease (JIA) and ocular complications or visual loss. On the other hand, elevated flare (≥20 photons/msec) has been found to be a strong predictor of complications and visual loss. Laser flare photometry is therefore an essential tool in the follow-up of children with chronic anterior uveitis.

Idiopathic Intermediate Uveitis (Pars Planitis)

According to the anatomic classification of uveitis by the Standardization of Uveitis Nomenclature (SUN) Working Group, the term “intermediate uveitis” defines a subset of uveitis where the vitreous is the primary site of inflammation. Pars planitis is a diagnostic term that defines a subset of idiopathic intermediate uveitis where there is snowbank or snowball formation. This disease typically affects children and adolescents. The association of intermediate uveitis with a systemic disease is very rare in children. Associations between idiopathic intermediate uveitis and HLA-DR2 and HLA-DR15 have been reported suggesting an immunogenetic predisposition. A strong association of multiple sclerosis with the same HLA antigens suggests a common genetic background.

Young children with pars planitis are usually asymptomatic and diagnosed during a routine ophthalmologic examination. Some children are diagnosed only after significant visual impairment or the development of complications that cause leukocoria or strabismus. Most children have bilateral symmetrical involvement.

Typical clinical findings include mild to moderate anterior segment inflammation, diffuse vitreous cells and haze, and snowballs and snowbanks located inferiorly (Fig. 4). Band keratopathy, peripheral corneal endotheliopathy (Fig. 5), and posterior synechiae may be seen in childhood pars planitis but are very rare in adults. Optic disc edema and cystoid macular edema are the most frequent complications.

Neovascularization of the optic disc or associated with snowbanks may cause vitreous hemorrhage and is more common in children than adults with pars planitis. Inferior peripheral
retinoschisis is another complication that develops almost exclusively in children (Fig. 6).\textsuperscript{35} Dense vitreous condensation may cause leukocoria, sometimes mistaken for cataracts (Fig. 7). However, posterior subcapsular cataract may also develop early in the course of the disease.\textsuperscript{36} Although vitreous haze and cataracts may cause amblyopia in a young child with pars planitis, cystoid macular edema is the leading cause of visual morbidity.\textsuperscript{34,35} In a long-term follow-up study, visual prognosis was reported to be good despite the high rate of ocular complications in children with pars planitis. However, a recent study has shown that children with onset of disease at 7 years of age or younger were at higher risk of complications such as cataract, glaucoma, and vitreous hemorrhage, and had worse visual prognosis than older children.\textsuperscript{37} Periocular corticosteroid injections and short-term oral steroids are used in patients who have sight-threatening intraocular inflammation, especially cystoid macular edema. Repeated corticosteroid injections may induce ocular hypertension.\textsuperscript{34} Methotrexate and cyclosporine may be used as steroid-sparing agents. Children with severe intermediate uveitis of the pars planitis type may even require treatment with biologic agents. In a retrospective analysis of 20 children with refractory uveitis treated with infliximab, 8 had idiopathic pars planitis.\textsuperscript{38} Infliximab infusions could be discontinued in 2 of them after 7 and 12 infusions because remission could be sustained with only antimetabolites. Intraocular inflammation was controlled in all of the remaining 6 pars planitis patients with repeated infliximab infusions and a concomitant antimetabolite agent without any need for oral corticosteroids.\textsuperscript{38}

**Behçet Uveitis**

The peak age of onset for Behçet disease is in the third or fourth decade of life. Although the onset of recurrent oral ulcers in childhood is not uncommon, patients typically fulfill the diagnostic criteria after the age of 16 years. There are no internationally accepted diagnostic
criteria for childhood-onset Behçet disease. In a recent international registry of patients suspected of pediatric Behçet disease, the presenting symptom was isolated recurrent oral ulcers in 83%, and the diagnosis was confirmed by an expert committee in 62% of registered cases. Uveitis was less common (34%) in this group than in adults. From an ophthalmological point of view, pediatric Behçet uveitis is defined as onset of uveitis at 16 years of age or younger irrespective of the age for fulfilling the diagnostic criteria. There may be variations in the prevalence of pediatric Behçet disease in different ethnic groups or geographic regions. In an international retrospective survey, more than half of the children with Behçet uveitis were from Middle Eastern countries as compared to only 2.4% from East/South Asia, in contrast 19.2% of adults belonged to the latter ethnic group. However, several sources of bias may have confounded the results of this survey. Even in Turkey, one of the countries with the highest prevalence of Behçet disease, only 3.5% of patients with Behçet uveitis are in the pediatric age group [unpublished data from the Turkish Registry of Uveitis (BUST study)].

Mean age at onset of pediatric Behçet uveitis is in late childhood (10-15 years). A positive family history has been reported in 20-47% of pediatric cases from endemic areas, implying the role of genetic factors in the early onset of the disease. Otherwise, the clinical picture in children is not different from adults. The majority of patients have bilateral involvement and recurrent panuveitis with retinal vasculitis. Cataract, intraocular pressure elevation, macular edema or maculopathy, and optic atrophy are the most common complications. While visual prognosis has been reported to be better than adults in some series, individual variability of the disease course, response to treatment and visual outcome has been reported by others. Children with posterior segment involvement require immunosuppressive therapy. Biologic agents are used in patients refractory to conventional immunosuppressive therapy. In a series of seven patients with corticosteroid dependent Behçet uveitis, treatment with interferon-alpha showed a corticosteroid-sparing effect with induction of remission in five patients; remission was sustained in four of them even after discontinuation of treatment in three.

Tubulointerstitial Nephritis and Uveitis (TINU) Syndrome

TINU is an uncommon syndrome accounting for 1.7% of all cases of adult uveitis. However, it is a more common cause of uveitis in children and adolescents with a median age of onset of 15 years. Diagnosis is based on the concurrence of acute tubulointerstitial nephritis (TIN) and bilateral acute anterior uveitis. Uveitis may not occur simultaneously, but may precede or more commonly follow renal disease. For a definite diagnosis, a renal biopsy may be performed. A clinical diagnosis of TIN is often based on the presence of systemic symptoms, including fever, weight loss, abdominal and flank pain, and arthralgia associated with renal dysfunction evidenced by increasing urea and creatinine levels, proteinuria, microhematuria, and glycosuria. An elevated urinary beta-2-microglobulin level has been reported as a very helpful laboratory marker. The typical presentation of TINU is an acute bilateral anterior uveitis, often with pain and photophobia. While topical corticosteroids may be sufficient in such cases, systemic corticosteroids and even immunosuppressive therapy may be required for renal disease or for patients who develop chronic recurrent anterior uveitis leading to ocular complications. Atypical cases with posterior or panuveitis may also require more aggressive treatment. Visual prognosis is generally good. In a recent retrospective study of 26 Finnish children with TIN, bilateral anterior uveitis was found in 12 subjects (46%). No correlation was found between renal disease and uveitis which preceded TIN by one month in one patient and followed TIN by 2 weeks to 15 months in others. Four of the 12 patients (33%) developed chronic uveitis and remission was achieved...
only after anti-tumor necrosis factor (TNF) treatment in one of them.51

Sarcoidosis

Childhood sarcoidosis is a rare multisystemic granulomatous inflammatory disorder. While older children may present with pulmonary involvement, young children typically present with a triad of arthritis, skin lesions and uveitis. Serum angiotensin-converting enzyme levels may be misleading because children tend to have higher levels than adults.52 Although a biopsy specimen showing non-caseating granulomatous inflammation is required for a definite diagnosis, the clinical diagnosis of ocular sarcoidosis can be made, at least in older children, based on typical signs of ocular disease and presence of laboratory abnormalities.53

Anterior uveitis is the most common type of involvement in children with sarcoidosis. Granulomatous KPs, iris nodules, and peripheral and broad-based posterior synechiae are typical findings. Chronic uncontrolled anterior uveitis may lead to complications such as band keratopathy cataracts, and glaucoma. Sometimes it is difficult to differentiate this clinical picture from JIA-associated uveitis. Inflammation of the posterior segment in the form of retinal vasculitis or multifocal choroiditis can be seen in sarcoidosis; however, intraocular inflammation is typically confined to the anterior segment in JIA-associated uveitis although posterior segment findings may develop as a complication of uncontrolled anterior uveitis.

Familial juvenile systemic granulomatosis, also known as Blau syndrome, has an autosomal dominant mode of inheritance and is characterized by granulomatous polyarthritis, skin rash and acute granulomatous anterior uveitis resembling sarcoidosis in young children.54,55 Since Blau syndrome is clinically indistinguishable from early-onset sarcoidosis, family history is an essential component in the assessment of children who present with these manifestations. The genetic mutation for both has been shown to involve the CARD15/NOD2 gene on chromosome 16q12, inherited in an autosomal dominant pattern in Blau syndrome but arising de novo in infantile sarcoidosis.56

TREATMENT OF NONINFECTIOUS UVEITIS IN CHILDREN

Exclusion of an infectious cause of uveitis and masquerade syndromes is of utmost importance before the administration of nonspecific anti-inflammatory and immunomodulatory treatment. Corticosteroids remain first-line treatment for noninfectious uveitis in children. Topical corticosteroids are initially used for treatment of anterior segment inflammation. Periocular or subtenon corticosteroid injections may be used for treatment of intermediate or posterior uveitis, especially in unilateral cases or for the treatment cystoid macular edema. Prolonged use of topical corticosteroids and repeated periocular injections are associated with a higher risk of ocular complications in children.57-59 Intraocular pressure elevation and steroid-induced glaucoma occur more rapidly and may be refractory to treatment in children. It is difficult to detect and monitor intraocular pressure elevation especially in young, noncompliant children. Multiple periocular injections may also result in systemic corticosteroid complications.60 Intravitreal injections may prevent systemic side effects, but potential risks and rate of ocular complications are higher.

Systemic corticosteroids are used only for short-term treatment in children because of significant systemic side effects associated with their prolonged use, including cushingoid status, growth retardation, weight gain, hypertension, osteoporosis, gastrointestinal disturbance, psychosis and electrolyte imbalance. The usual induction dose of oral prednisolone is 1-2mg/kg. Intravenous pulse methyl-prednisolone 30mg/kg may be preferred when more rapid and potent action is needed. Patients who do not adequately respond to high dose corticosteroids will need immunosuppressive treatment. For patients who become corticosteroid-dependent, a corticosteroid-sparing immunosuppressive agent is administered. In patients who present with serious ocular complications and risk factors for development of new complications,
immunosuppressive agent(s) combined with corticosteroids may be started at initial visit. Methotrexate is the most widely used first-line immunomodulatory agent in children with uveitis because of its long-term safety profile in this age group. In a recently reported series of JIA-associated uveitis, improvement of inflammation was achieved in 82% of patients treated with methotrexate for at least 3 months. A longer duration of inactivity during methotrexate therapy was found to be associated with a lower risk of relapse after discontinuation of this agent. Second-line immunosuppressive agents include azathioprine, cyclosporine and mycophenolate. Alkylating agents, such as cyclophosphamide and chlorambucil, are generally avoided in children because of serious potential side effects. These agents have been used in children with emergency situations such as systemic lupus erythematosus or other life-threatening vasculitides.

Anti-TNF agents are used in patients who fail to respond to conventional immunosuppressive therapy and are at a high risk of visual loss. Both infliximab and adalimumab have been successfully used for treatment of resistant pediatric uveitis. The convenience of subcutaneous administration, stable serum concentrations, and more favorable safety profile are advantages of adalimumab over intravenous infliximab infusions for treatment of uveitis in children. However, the fast-onset and potent anti-inflammatory effect of infliximab may be desirable for immediate control of intraocular inflammation, for example in children who need emergency ocular surgery. Another anti-TNF agent, etanercept, which is effective in the treatment of rheumatic disease in children, is not recommended for treatment of uveitis. Smith et al reported no significant difference between placebo and etanercept in a randomized controlled trial. Furthermore, several cases of new-onset uveitis have been reported in patients receiving etanercept for rheumatologic disorders. In patients refractory to anti-TNF agents, alternative biologic agents may be tried such as anakinra, daclizumab, abatacept, rituximab, and tocilizumab. Experience with these agents is currently limited to small series of selected patients. Furthermore, potential serious adverse effects such as an increased risk of opportunistic infections and malignancies should be carefully weighed against benefits of biologic therapy in this particular age group who have long life expectancy.

Conflicts of Interest
None.

REFERENCES
1. Paivönsalo-Hietanen T, Tuominen J, Saari KM. Uveitis in children: population-based study in Finland. Acta Ophthalmol Scand 2000;78:84-88.
2. Edelsten C, Reddy MA, Stanford MR, Graham EM. Visual loss associated with pediatric uveitis in English primary and referral centers. Am J Ophthalmol 2003;135:676-680.
3. Tugal-Tutkun I, Havrlikova K, Power WJ, Foster CS. Changing patterns in uveitis of childhood. Ophthalmology 1996;103:375-383.
4. Pivetti-Pezzi P. Uveitis in children. Eur J Ophthalmol 1996;6:293-298.
5. Soylu M, Ozdemir G, Anli A. Pediatric uveitis in southern Turkey. Ocul Immunol Inflamm 1997;5:197–202.
6. Stoffel PB, Sauvain MJ, von Vigier RO, Beretta-Piccoli BC, Ramelli GP, Bianchetti MG. Non-infectious causes of uveitis in 70 Swiss children. Acta Paediatr 2000;89:955–958.
7. de Boer J, Wulffraat N, Rothova A. Visual loss in uveitis of childhood. Br J Ophtalmol 2003;87:879–884.
8. Kadayifcilar S, Eldern B, Turner B. Uveitis in childhood. J Pediatr Ophthalmol Strabismus 2003;40:335–340.
9. Azar D, Martin F. Paediatric uveitis: a Sydney clinic experience. Clin Exp Ophtalmol 2004;32:468-471.
10. Rosenberg KD, Feuer WJ, Davis JL. Ocular complications of pediatric uveitis. Ophthalmology 2004;111:2299–2306.
11. Kump LI, Cervantes-Castaneda RA, Androudi SN, Foster CS. Analysis of pediatric cases at a tertiary referral center. Ophthalmology 2005;112:1287-1292.
12. Ben Ezra D, Cohen E, Maftzir G. Uveitis in children and adolescents. Br J Ophtalmol 2005;89:444-448.
13. Khairallah M, Attia S, Zaouali S, Yahia SB, Kahloun R, Messaoud R et al. Pattern of childhood-onset uveitis in a referral center in Tunisia, North Africa.
Ocular Immunol Inflamm 2006;14:225-231.

14. Rathinam SR, Namperumalsamy P. Global variation and pattern changes in epidemiology of uveitis. Indian J Ophthalmol 2007;55:173-183.

15. Kazokoglu H, Oral S, Tugal-Tutkun I, Mirza E, Akova Y, Ozyazgan Y, et al. Demographic and clinical features of uveitis in tertiary centers in Turkey. Ophthalmic Epidemiol 2008;15:285-293.

16. Smith JA, Mackensen F, Sen HN, Leighton JF, Watkins AS, Pyatetsky D, et al. Epidemiology and course of disease in childhood uveitis. Ophthalmology 2009;116:1544-1551.

17. Paroli MP, Spinucci G, Liverani M, Monte R, Pezzi PP. Uveitis in childhood: an Italian clinical and epidemiological study. Ocul Immunol Inflamm 2009;17:238.

18. Hamade IH, Al Shamsi HN, Al Dhibi H, Chacra CB, Abu El-Asrar AM, Tabbara KF. Uveitis survey in children. Br J Ophthalmol 2009;93:569-572.

19. Kotaniemi K, Savolainen A, Karma A, Aho K. Recent advances in uveitis of juvenile idiopathic arthritis. Surv Ophthalmol 2003;48:489-502.

20. Petty RE, Smith JR, Rosenbaum JT. Arthritis and uveitis in children: A pediatric rheumatology perspective. Am J Ophthalmol 2003;135:879-884.

21. Kesen MR, Settur V, Goldstein DA. Juvenile idiopathic arthritis-related uveitis. Int Ophthalmol Clin 2008;48:21-38.

22. Cassidy J, Kivel J, Lindsley C, Nocton J. Section on Rheumatology, Section on Ophthalmology. Ophthalmologic examinations in children with juvenile rheumatoid arthritis. Pediatrics 2006;117:1843-1845.

23. Keenan JD, Tessler HH, Goldstein DA. Granulomatous inflammation in juvenile idiopathic arthritis-associated uveitis. J AAPOS 2008;12:546-550.

24. Kump LI, Cervantes-Castaneda RA, Androidi SN, Reed GF, Foster CS. Visual outcomes in children with juvenile idiopathic arthritis-associated uveitis. Ophthalmology 2006;113:1874-1877.

25. Thorne JE, Woreta F, Kedhar SR, Dunn JP, Jabs DA. Juvenile idiopathic arthritis-associated uveitis: incidence of ocular complications and visual acuity loss. Am J Ophthalmol 2007;143:840-846.

26. Ducos de Labitte G, Terrada C, Tran TH, Cassoux N, LeHoang P, Kodjikian L, et al. Maculopathy in uveitis of juvenile idiopathic arthritis: an optical coherence tomography study. Br J Ophthalmol 2008;92:64-69.

27. Davis JL, Dacanay LM, Holland GN, Berrocal AM, Giese MJ, Feuer WJ. Laser flare photometry and complications of chronic uveitis in children. Am J Ophthalmol 2003;135:763-771.

28. Holland GN. A reconsideration of anterior chamber flare and its clinical relevance for children with chronic anterior uveitis (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 2007;105:344-364.

29. Sijssens KM, Rothova A, van de Vijver DA, Stilma JS, de Boer JH. Risk factors for the development of cataract requiring surgery in uveitis associated with juvenile idiopathic arthritis. Am J Ophthalmol 2007;144:574-579.

30. Holland GN, Denove CS, Yu F. Chronic anterior uveitis in children: clinical characteristics and complications. Am J Ophthalmol 2009;147:667-678.

31. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005;140:509-516.

32. Am J Ophthalmol 2006;143:840-846.

33. Ocul Immunol Inflamm 2007;15:285-293.

34. Int Ophthalmol Clin 2008;48:61-74.

35. J Pediatr Ophthalmol Strabismus 2007;44:288-293.

36. J Pediatr Ophthalmol Strabismus 2001;29:81-84.

37. Int Ophthalmol Clin 2009;147:667-678.

38. Int Ophthalmol Clin 2007;105:344-364.

39. Int Ophthalmol Clin 2009;147:667-678.

40. Int Ophthalmol Clin 2007;105:344-364.

41. Int Ophthalmol Clin 2009;147:667-678.

42. Int Ophthalmol Clin 2007;105:344-364.

43. Int Ophthalmol Clin 2009;147:667-678.

44. Int Ophthalmol Clin 2007;105:344-364.

45. Int Ophthalmol Clin 2007;105:344-364.

46. Int Ophthalmol Clin 2007;105:344-364.

47. Int Ophthalmol Clin 2007;105:344-364.

48. Int Ophthalmol Clin 2007;105:344-364.

49. Int Ophthalmol Clin 2007;105:344-364.

50. Int Ophthalmol Clin 2007;105:344-364.
Chams H, Ohno S. Low prevalence of juvenile-onset Behçet’s disease with uveitis in East/South Asian people. Br J Ophthalmol 2009;93:1428-1430.

41. Tugal-Tutkun J, Urgancioglu M. Childhood-onset uveitis in Behçet disease: A descriptive study of 36 cases. Am J Ophthalmol 2003; 136:1114-1119.

42. Borlu M, Uksal Ü, Ferahbas A, Evereklioglu C. Clinical features of Behçet’s disease in children. Int J Dermatol 2006;45:713-716.

43. Kesen MR, Goldstein DA, Tessler HH. Uveitis associated with pediatric Behçet disease in the American Midwest. Am J Ophthalmol 2008;146:819-827.

44. Citirik M, Berker N, Songur MS, Soykan E, Zilelioglu O. Ocular findings in childhood-onset Behçet disease. J AAPOS 2009;13:391-395.

45. Sungur GK, Hazirolan D, Yalvac I, Ozer PA, Yuksel D, Vural ET, et al. Clinical and demographic evaluation of Behçet disease among different pediatric age groups. Br J Ophthalmol 2009;93:83-87.

46. Guillame-Czitrom S, Berger C, Pajot C, Bodaghi B, Wechsler B, Kone-Paut I. Efficacy and safety of interferon-alpha in the treatment of corticodependent uveitis of paediatric Behçet’s disease. Rheumatology (Oxford) 2007;46:1570-1573.

47. Mackensen F, Smith JR, Rosenbaum JT. Enhanced recognition, treatment, and prognosis of tubulointerstitial nephritis and uveitis syndrome. Ophthalmology 2007;114:995-999.

48. Mandeville JT, Levinson RD, Holland GN. The tubulointerstitial nephritis and uveitis syndrome. Surv Ophthalmol 2001;46:195-208.

49. Levinson RD. Tubulointerstitial nephritis and uveitis syndrome. Int Ophthalmol Clin 2008;48:51-59.

50. Mackensen F, Billing H. Tubulointerstitial nephritis and uveitis syndrome. Curr Opin Ophthalmol 2009;20:525-531.

51. Jahnkainen T, Ala-Houhala M, Karikoski R, Kataja J, Saarelma V, Nuutinen M. Clinical outcome and occurrence of uveitis in children with idiopathic tubulointerstitial nephritis. Pediatr Nephrol 2011;26:291-299.

52. Shetty AK, Gedalia A. Childhood sarcoidosis: A rare but fascinating disorder. Pediatr Nephrol Online J 2008;6:16.

53. Herbert CP, Rao NA, Mochizuki M; members of Scientific Committee of First International Workshop on Ocular Sarcoidosis. International criteria for the diagnosis of ocular sarcoidosis: results of the first International Workshop on Ocular Sarcoidosis (IWOS). Ocul Immunol Inflamm 2009;17:160-169.

54. Manouvrier-Hanu S, Puech B, Piette F, Boute- Benejean O, Desbonnet A, Duguesnoy B, et al. Blau syndrome of granulomatous arthritis, iritis, and skin rash: a new family and review of the literature. Am J Med Genet 1998;76:217-221.

55. Glass DA 2nd, Maender J, Metry D. Two pediatric cases of Blau syndrome. Dermatol Online J 2009;15:5.

56. Becker ML, Rose CD. Blau syndrome and related genetic disorders causing childhood arthritis. Curr Rheumatol Rep 2005;7:427-433.

57. Simonini G, Cantarini L, Bresci C, Lorusso M, Galeazzi M, Cimaz R. Current therapeutic approaches to autoimmune chronic uveitis in children. Autoimmun Rev 2010;9:674-683.

58. Levy-Clarke GA, Nussenblatt RB, Smith JA. Management of chronic pediatric uveitis. Curr Opin Ophthalmol 2005;16:281-288.

59. Zierhut M, Doycheva D, Biester S, Stübiger N, Kümerle-Deschner J, Deuter C. Therapy of uveitis in children. Int Ophthalmol Clin 2008;48:131-152.

60. Habot-Wilner Z, Sallam A, Roufas A, Kabasele PM, Grigg JR, McCluskey P, et al. Periocular corticosteroid injection in the management of uveitis in children. Acta Ophthalmol 2010;88:299-304.

61. Kalinina Ayuso V, van de Winkel EL, Rothova A, de Boer JH. Relapse rate of uveitis post-methotrexate treatment in juvenile idiopathic arthritis. Am J Ophthalmol 2011;151:217-222.

62. Ardoin SP, Kredich D, Rabinovich E, Schanberg LE, Jaffe GJ. Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up. Am J Ophthalmol 2007;144:844-849.

63. Rajaraman RT, Kimura Y, Li S, Haines K, Chu DS. Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology 2006;113:308-314.

64. Kahn P, Weiss M, Imundo LF, Levy DM. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology 2006;113:860-864.

65. Vazquez-Cobian LB, Flynn T, Lehman TJ. Adalimumab therapy for childhood uveitis. J Pediatr 2006;149:572-575.

66. Biester S, Deuter C, Michels H, Haefner R, Kuemmerle-Deschner J, Doycheva D, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 2007;91:319-324.

67. Gallagher M, Quinones K, Cervantes-Castaneda RA, Yilmaz T, Foster CS. Biological response modifier therapy for refractory childhood uveitis. Br J Ophthalmol 2007;91:1341-1344.

68. Tynjala P, Kotaniemi K, Lindahl P, Latva K, Aalto K, Honkanen V, et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior
uveitis. *Rheumatology (Oxford)* 2008;47:339-344.

69. Mansour AM. Adalimumab in the therapy of uveitis in childhood. *Br J Ophthalmol* 2007;91:274-276.

70. Smith JA, Thompson DJ, Whitcup SM, Suhler E, Clarke G, Smith S, et al. A randomized, placebo-controlled, double-masked clinic trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. *Arthritis Rheum* 2005;53:18-23.

71. Kaipiainen-Seppanen O, Leino M. Recurrent uveitis in a patient with juvenile spondyloarthropathy associated with tumour necrosis factor alpha inhibitors. *Ann Rheum Dis* 2003;62:88-89.

72. Reddy AR, Backhouse OC. Does etanercept induce uveitis? *Br J Ophthalmol* 2003;87:925.

73. Sen HN, Levy-Clarke G, Faia LJ, Li Z, Yeh S, Barron KS, et al. High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis. *Am J Ophthalmol* 2009;148:696-703.

74. Zulian F, Balzarini M, Falcini F, Martini G, Alessio M, Cimaz R, et al. Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. *Arthritis Care Res (Hoboken)* 2010;62:821-825.

75. Heiligenhaus A, Miserocchi E, Heinz C, Gerloni V, Kotaniemi K. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). *Rheumatology (Oxford)* 2011;50:1390-1394.